A 70-year-old man was admitted due to dyspnoea (NYHA class III). In 1989, he underwent an aortic valve replacement using a Carpentier-Edwards bioprosthesis no. 21 and a left internal mammary artery-left anterior descending coronary bypass. In 2003, a laryngectomy and post-operative radiotherapy were performed because of laryngeal cancer. He then decided to stop smoking. At admission, blood pressure was 121/50 mmHg, and a murmur and peripheral signs of severe aortic regurgitation were noted. Transthoracic and transoesophageal echocardiography showed degeneration of the bioprosthesis with severe regurgitation due to cusp prolapse, left ventricular ejection fraction of 50%, and systolic pulmonary artery pressure at 60 mmHg (Panel A).
The coronary angiogram showed three-vessel disease with a patent graft.
The patient was formally denied surgical valve replacement because of high risk of mediastinitis due to laryngostomy and the impossibility of double thoracotomy due to radiation skin disease. In addition, the mortality risk predicted by the EuroSCORE was 35%.
The indication for trans-catheter aortic valve implantation was retained on a compassionate basis. After informed consent, a CoreValve w Revalving System was successfully implanted into the Carpentier -Edwards bioprosthesis via femoral access (Panels B and C). The hospital course was uncomplicated, with immediate functional improvement. At discharge, transthoracic echocardiography confirmed the adequate position of the prosthesis, the absence of residual regurgitation (Panel D), a left ventricular ejection fraction of 50%, and a systolic pulmonary artery pressure at 35 mmHg.
Despite the limited current experience, this case of 'valve-in-valve' implantation suggests that the technique is feasible and might be an attractive alternative to surgery for selected high-risk patients with severe dysfunction of degenerated bioprosthesis. 
